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CIostridium perfiingens iota toxin ADP-ribosylates actin. Substrates of C. perfringens toxin are both non- 
muscle /I/y-a&in and skeletal muscle actin. This finding suggests that C. perfringens iota ADP-ribosylates 
the same amino acid in skeletal muscle and non-muscle actin as does C. botulinwn C2 toxin in non-muscle 
actin. Protein chemical analysis involving thermolysin cleavage on [32P]ADP-ribosylated actin or tryptic di- 
gestion followed by a secondary thermolysin cleavage of the radiolabelled fragments showed one major site 
of ADP-ribosylation. From its amino acid composition and sequence, the radiolabelled peptide was identi- 
fied as peptide 175-177, locating the acceptor ADP-ribosyl amino acid as Arg-177. 
ADP-ribosylation; Actin; Iota toxin; C2 toxin; (C. perfringens, C. botulinurn) 
1. INTRODUCTION 
Various microbial toxins such as diphtheria, 
cholera and pertussis toxins interfere with 
eukaryotic cell functions by ADP-ribosylation of 
regulatory GTP-binding proteins [l-3]. Recently, 
it has been shown that Clostridium botulinum C2 
toxin and C. perfrngens iota toxin belong to a new 
class of microbial ADP-ribosyltransferases, whose 
eukaryotic substrate is actin [4-71. Both clostridial 
toxins show striking similarities: they are binary in 
structure and consist of a low- and a high- 
molecular-mass component [8,9]. In both cases, 
the high-molecular-mass components (iota toxin, 
78 kDa; C2 toxin, 88 kDa) are apparently involved 
in binding of the toxins to eukaryotic cell mem- 
brane, while the low-molecular-mass components 
(-50 kDa) possess ADP-ribosyltransferase activity 
[6,10,11]. Both toxins apparently modify G- but 
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not F-actin and ADP-ribosylation caused by either 
toxin severely reduces the ability of actin to 
polymerize [4,5,7]. However, both toxins are dif- 
ferent in their substrate specificity. Whereas iota 
toxin ADP-ribosylates non-muscle and skeletal 
muscle actin with similar efficiency, the latter is 
almost not modified by C2 toxin [7]. Recently, it 
has been shown that C2 toxin ADP-ribosylates 
platelet P/y-actin in Arg-177 [12]. In order to gain 
more insight into the substrate specificity of the 
toxins, in the present study we analyzed the ADP- 
ribose acceptor amino acid of skeletal muscle actin 
modified by iota toxin. 
2. MATERIALS AND METHODS 
2.1. Materials 
C. perfringens iota toxin and C. botulinum C2 
toxin were purified from culture medium of C. 
perfringens type E strain CN 5063 and C. 
botulinum type C strain 9243, kindly donated by 
Drs S. Thorley (Wellcome Biotech, Beckenham, 
England) and S. Nakamura (Kanazawa, Japan), 
respectively, essentially as described [9]. All other 
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reagents were of analytical grade and obtained 
from commercial sources. 
2.2. Purification of actin isoforms 
Human platelet cytoskeletal actin was purified 
according to [13] with an additional gel filtration 
step as in [ 121. Rabbit skeletal muscle was purified 
as described [14]. 
2.3. SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis was per- 
formed according to [15]. Gels were stained with 
Coomassie brilliant blue, destained, and 
autoradiographed on Kodak X-Omat AR films. 
2.4. ADP-ribosylation assay 
ADP-ribosylation was performed as in [5]. 
Briefly, about 1 mg rabbit skeletal actin (in G- 
buffer [14]) was ADP-ribosylated in a medium 
containing 10 mM thymidine, 10 mM dithio- 
threitol, 1 mM MgC12, 1 mM EDTA, 1-4~8 iota 
toxin, 10pM [32P]NAD (about 10 ,&i) and 
triethanolamine-HCI (pH 7.5) in a total volume of 
1 ml for 30 min at 37°C. Thereafter, unlabelled 
NAD was added to a final concentration of 
0.5 mM and the reaction was continued for a fur- 
ther 2 h. Unreacted NAD was separated by cen- 
trifugation through centricon 30 (Amicon, Witten, 
FRG). Thereafter, actin was denatured in 3 M 
guanidine-HCl and precipitated in ethanol. 
2.5. Protein-chemical analysis of ADP- 
ribosylated actin 
The identification of ADP-ribosylated amino 
acid in actin was carried out essentially as de- 
scribed for C. botulinum C2 toxin-ADP- 
ribosylated actin [12]. Briefly, 1 mg [32P]ribosy- 
lated actin ethanol precipitate was dissolved in for- 
mic acid (98%) at 0°C and dialyzed against water 
with three changes over 4 h. The actin solution was 
made 0.5% in ammonium bicarbonate and di- 
gested with trypsin (25 pg) for 2 h at 37°C and 
finally lyophilized. Peptides were resuspended in 
0.5 ml of pH 6.5 buffer (10% pyridine, 0.5% 
acetic acid) and the soluble and insoluble peptides 
separated by centrifugation in Eppendorf tubes. 
For further cleavage, the insoluble fragments were 
redissolved in 3 M NHdOH, diluted in 10 ~01s 
water, adjusted to pH 8-9 with acetic acid and 
digested with thermolysin (1: 50 enzyme/substrate 
ratio) for 3 h at 55°C. The soluble tryptic peptides 
and the thermolysin secondary peptides were se- 
parated by a ‘three-dimensional’ combination of 
paper electrophoretic and chromatographic tech- 
niques, and detected by diluted fluorescamine 
staining [16]. The radioactive peptides were lo- 
cated by autoradiography, recovered from the 
paper by elution with pH 6.5 buffer, identified by 
amino acid analysis using a Biotronik (FRG) 
amino acid analyzer and sequenced with a gas- 
phase sequenator [17] equipped with an on-line 
phenylthiohydantoin amino acid analyzer (Applied 
Biosystems, USA). 
In a separate experiment, [32P]ADP-ribosylated 
actin (0.5 mg) was also directly digested with ther- 
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Fig.1. ADP-ribosylation of human platelet and rabbit 
skeletal muscle actin by C. botulinum C2 toxin and C. 
perfringens iota toxin. Rabbit skeletal muscle G-actin 
(4pg) (lanes l-3) and human platelet G-actin (2pg) 
(lanes 4-6) were ADP-ribosylated with C2 toxin 
(1 pg/ml; lanes 1,4), iota toxin (0.4pg/ml; lanes 2,5), 
and without toxin (lanes 3,6) in the presence of 5 PM 
[32P]NAD (-0.2 &i) for 30 min as described. Proteins 
were separated by SDS-polyacrylamide gel electro- 
phoresis and detected by Coomassie staining (A) or 
autoradiography (B). 
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molysin. The fragmentation was performed essen- 
tially as for the tryptic hydrolysis using an 
enzyme/substrate ratio of 1:60 (by wt). Ther- 
molysin peptides were separated, detected, and 
identified as described above. 
3. RESULTS 
Fig.1 shows that human platelet P/y-actin was 
ADP-ribosylated by both C. perfringens iota toxin 
(0.08 pg/ml) and C. botulinurn C2 toxin 
(1 pg/ml). Minor labelling by iota toxin was due to 
application of a submaximally effective concentra- 
tion of the toxin. Even at such a low concentration 
of iota toxin, rabbit skeletal muscle a-actin was 
also ADP-ribosylated. In contrast, C2 toxin did 
not ADP-ribosylate skeletal muscle actin at con- 
centrations maximally effective in modifying 
platelet actin. 
In order to locate the site of modification, 
[32P]ADP-ribosylated skeletal muscle actin was 
digested with thermolysin. Paper peptide mapping, 
followed by autoradiography, revealed a single 
chromatography 
Fig.2. Two-dimensional paper peptide map of the 
thermolysin peptides of [32P]ADP-ribosylated skeletal 
muscle actin. The start position is indicated by (0.); the 
first separation is by horizontal paper electrophoresis at 
pH 6.5 followed by vertical separation by paper 
chromatography. Only the anodic side (containing the 
acidic peptides) of the autoradiogram is shown. Note the 
Fig.3. Traces of phenylthiohydantoin amino acid 
analyses of cycles l-4 of the ADP-ribosylated 
thermolysin peptide of skeletal muscle actin. 1 nmol was 
loaded on the sequenator and 40% of the amount of 
PTH amino acid was analyzed. The initial coupling yield 
was 42%. Numbers in parentheses indicate pmol 
recovered. DPTU indicates the diphenylthiourea noted 
as the major byproduct and serving as an internal 
presence of a single major radioactive spot. reference. 
major radiolabelled spot (fig.2). Staining the pep- 
tide fingerprint with diluted fluorescamine showed 
that no other thermolysin peptide comigrated with 
the radiolabelled peptide. This was further con- 
firmed from the amino acid composition (Ile, 1.0; 
Met, 0.8; Arg, 0.7) and consecutive sequence 
analysis of the labelled peptide concluding for a se- 
quence Ile-Met-X (fig.3). From the composition 
(the presence of equimolar quantities of arginine in 
the hydrolysate), the identified sequence (Ile-Met), 
and the known specificity of thermolysin, the 
ADP-ribosyl acceptor region could be identified as 
region 175-177. The presence of arginine in the 
acid hydrolysate but absence as a phenylthio- 
hydantoin derivative in cycle 3 of the automated 
gas-phase degradation identifies Arg- 177 as the 
modified residue. 
The radiolabelled peptide was recovered with a 
final yield of 20% of total actin digested. Previous 
I Ile 2 Met 
(168) (164) 
DPTU *II-d DK1 (2! 
I 4 
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studies [7] have shown that the extent of in vitro 
ADP-ribosylation of skeletal muscle actin by the 
iota toxin amounts to values varying from 25 to 
50% of total actin. This means that the radiola- 
belled fragment was recovered in yields ranging 
from 80 to 40% of maximally recoverable peptide. 
Such values are high when paper separation and 
elution techniques are used for purification. In ad- 
dition, no other major radiolabelled peptide was 
observed and the amount of radioactivity 
recovered in this peptide was as high as 70% of the 
initial label. These high recovery values strongly 
argue for the existence of a unique site of ADP- 
ribosylation. Unlike its nonmodified basic 
derivative, the ADP-ribosyl Ile-Met-Arg peptide 
migrates as an acidic peptide. Its relative elec- 
trophoretic mobility (0.2 according to the Offord 
plot) [18] and very low chromatographic mobility 
are both arguments for a covalently linked ADP- 
ribosyl group adding two negative charges, a mass 
of 519 Da and a strong hydrophilic nature to the 
original tripeptide. 
The position of the ADP-ribosylation acceptor 
amino acid was further confirmed from the results 
of a tryptic digestion of [32P]ADP-ribosyl skeletal 
muscle actin. Such digestion yields a peptide mix- 
ture, a fraction of which is soluble at pH 6.5 and 
another fraction remains insoluble. The radiolabel 
is equally divided over both fractions. The labelled 
soluble tryptic peptide was recovered from the 
paper and identified by sequencing as a mixture of 
peptide 96-l 13 and the region covering residues 
174-183. Previous actin amino acid studies [16] 
have shown that fragment 174-183 may be re- 
leased as a soluble peptide by a partial nonspecific 
cleavage at the His-173-Ala-174 peptide bond 
from the insoluble peptide 148-183. When the 
174-183 and 96-l 13 mixture was treated with 
thermolysin, a single labelled peptide could then be 
isolated, yielding an unambiguous composition 
and sequence corresponding with the region 
175-177. The same thermolysin fragment was also 
generated from the insoluble tryptic core fraction, 
this time originating from peptide 148-183. 
These results allow one to conclude that arginine 
at position 177 of skeletal muscle actin is the only 
major acceptor amino acid for the ADP- 
ribosylation by C. perfringens iota toxin. 
4. DISCUSSION 
Here we report that C. perfringens iota toxin 
modifies skeletal muscle cu-actin in Arg-177. It has 
been shown, previously, that C. botulinurn C2 tox- 
in, which ADP-ribosylates nonmuscle actin, but 
not that of skeletal muscle, also modifies actin in 
Arg-177 [12]. Thus, both toxins not only share the 
same substrate actin but also an identical acceptor 
amino acid. The modification of the identical 
amino acid explains the similarities found in the 
ADP-ribosylation of actin by either toxin, e.g. that 
phalloidin blocks the ADP-ribosylation and that 
modified actin loses its ability to polymerize. 
However, the present data do not explain why 
skeletal muscle actin can serve as substrate of iota 
toxin but not of C2 toxin. The difference in 
substrate specificity is most surprising because 
skeletal muscle and nonmuscle actin are highly 
homologous and differ only by about 6% [19]. It 
has been suggested, recently, that this difference 
may be due to the amino acid preceding Arg-177, 
which is leucine in nonmuscle actin and methionine 
in skeletal muscle actin. However, the data shown 
here indicate that exchange of leucine for 
methionine in skeletal muscle actin does not prin- 
cipally prevent an ADP-ribosylation of Arg-177, 
and suggest hat the structural requirements for the 
ADP-ribosylation of actin by these two toxins 
reside at another level. 
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